Published in AIDS Weekly, October 30th, 2000
"The present study was designed to determine whether the human leukocyte antigen (HLA) allogeneic T helper response stimulated by semi-allogeneic cell lines could be used as an in vitro model of immune-based therapy to stimulate HIV specific CTL," stated E. Grene and colleagues, U.S. National Cancer Institute, Maryland. "Semi-allogeneic cell hybrids were obtained by the fusion of peripheral blood mononuclear cells from HIV infected patients with the allogeneic beta 2-microglobulin-deficient FO1-12 melanoma cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.